Life Tech gets bigger in bioproduction with BAC buy
pharmafile | January 28, 2013 | News story | Manufacturing and Production |Â Â BAC, Life TechnologiesÂ
Life Technologies has expanded its position in bioprocessing technologies with the acquisition of Dutch protein purification specialist BAC.
Carlsbad, US-based Life Technologies said the deal will expand its capabilities and product offerings in biopharmaceutical research and manufacturing, and comes on the back of an expansive period for the company.
In 2012 the company entered into strategic business partnerships for its companion diagnostics business. It acquired Navigenics, Pinpoint and Compendia to underpin a new medical sciences division, and acquired distributors in China and Chile to help extend its presence in emerging markets.
The acquisition of BAC “positions Life Technologies as a leading provider of end-to-end solutions that are widely utilised in the bioprocess workflow”, said Tony Hunt, head of the company’s bioproduction business unit.
Specifically, the deal adds BAC’s CaptureSelect brand of affinity resins, based on molecules that bind with high affinity to specific proteins and can be used for separation and purification purposes, to Life Technologies’ Gibco brand of cell culture media and Poros chromatography resins used for purification.
Bioproduction sales at Life Technologies were down in the third quarter of 2012, but tend to fluctuate on a quarterly basis, said the firm in its third-quarter conference call, adding that it expects to see a rebound in this division when it reports fourth quarter revenues early next month.
“Combining BAC’s current portfolio and pipeline with our pre-existing portfolio expands Life’s product offering and enables us to compete more fully across the protein purification market,” said Hunt.
Laurens Sierkstra, chief executive of BAC plus 34 other BAC employees will join Life Technologies, which said the Dutch company’s manufacturing plant in Naarden and R&D facility in Leiden will remain in operation.
Phil Taylor
Related Content
BAC and Octapharma extend collaboration for G-CSF custom ligand
BAC, a specialist in antibody-based affinity purification technology has signed a licence agreement with Octapharma, …
